Status:
SUSPENDED
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study aims to investigate the efficacy and safety of gefitinib as neoadjuvant therapy in stage IIIA NSCLC patients.
Eligibility Criteria
Inclusion
- Patients pathological diagnosed with NSCLC,with EGFR sensitive mutation;
- Stage IIIA patients with technical operable disease evaluated by image and lab results;
- Patients without chemotherapy or targeted-therapy before;
- Inform Consent.
Exclusion
- Patients with malignant tumor other than lung cancer;
- Patients with other diseases such as cardiovascular disease that may hamper follow up;
- Patients that may not coordinate well,judged by researcher.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2016
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00986284
Start Date
September 1 2009
End Date
November 1 2016
Last Update
December 22 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China, 300060